表纸
市场调查报告书

毛细胞白血病:开发中产品分析

Hairy Cell Leukemia - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品编码 253659
出版日期 内容资讯 英文 125 Pages
订单完成后即时交付
价格
毛细胞白血病:开发中产品分析 Hairy Cell Leukemia - Pipeline Review, H1 2020
出版日期: 2020年04月30日内容资讯: 英文 125 Pages
简介

毛细胞白血病是罕见且病征缓慢的血液癌症,骨髓会制造过多B细胞(淋巴球)。症状有疲劳、容易出现瘀血、感染疾病复发、虚弱、体重减少等。危险因素有暴露在放射线、化学物质下等。治疗有外科手术、化疗、放射线治疗等。

本报告提供毛细胞白血病的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等相关的系统性资讯。

简介

  • 调查范围

毛细胞白血病;概要

毛细胞白血病 - 治疗药的开发

  • 开发中产品的概要
  • 在企业被开发了的开发平台
  • 企业开发中的产品

治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • AbbVie Inc
  • ARA Healthcare Pvt Ltd
  • Astellas Pharma Inc.
  • Cellectis SA
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Juno Therapeutics Inc
  • MedImmune LLC
  • Novartis AG

药物简介

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC12157IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 2, 1, 1 and 1 molecules, respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
    • Hairy Cell Leukemia - Overview
    • Hairy Cell Leukemia - Therapeutics Development
    • Hairy Cell Leukemia - Therapeutics Assessment
    • Hairy Cell Leukemia - Companies Involved in Therapeutics Development
    • Hairy Cell Leukemia - Drug Profiles
    • Hairy Cell Leukemia - Dormant Projects
    • Hairy Cell Leukemia - Discontinued Products
    • Hairy Cell Leukemia - Product Development Milestones
    • Appendix

    List of Tables

    • Number of Products under Development for Hairy Cell Leukemia, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Products under Development by Companies, H1 2020
    • Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Stage and Target, H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020
    • Number of Products by Stage and Route of Administration, H1 2020
    • Number of Products by Stage and Molecule Type, H1 2020
    • Hairy Cell Leukemia - Pipeline by AbbVie Inc, H1 2020
    • Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, H1 2020
    • Hairy Cell Leukemia - Pipeline by Cellular Biomedicine Group Inc, H1 2020
    • Hairy Cell Leukemia - Pipeline by Elsalys Biotech SA, H1 2020
    • Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, H1 2020
    • Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
    • Hairy Cell Leukemia - Pipeline by Incyte Corp, H1 2020
    • Hairy Cell Leukemia - Pipeline by Novartis AG, H1 2020
    • Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
    • Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, H1 2020
    • Hairy Cell Leukemia - Dormant Projects, H1 2020
    • Hairy Cell Leukemia - Discontinued Products, H1 2020

    List of Figures

    • Number of Products under Development for Hairy Cell Leukemia, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Top 10 Targets, H1 2020
    • Number of Products by Stage and Top 10 Targets, H1 2020
    • Number of Products by Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Routes of Administration, H1 2020
    • Number of Products by Stage and Routes of Administration, H1 2020
    • Number of Products by Molecule Types, H1 2020
    • Number of Products by Stage and Molecule Types, H1 2020